Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART

被引:5
作者
Bonnet, F
Savès, M
Morlat, P
Droz, C
Chêne, G
Peuchant, E
Bernard, N
Lacoste, D
Salamon, R
Beylot, J
机构
[1] Hop St Andre, Serv Med Interne & Malad Infectieuses, F-33075 Bordeaux, France
[2] Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France
[3] Hop St Andre, Biochim Lab, F-33075 Bordeaux, France
关键词
HIV; marker of immune activation; protease inhibitor; soluble tumor necrosis factor alpha receptor; soluble interleukin-2 receptor;
D O I
10.1023/A:1014475618504
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed the correlations between some plasma markers of immune activation (soluble receptors of interleukin 2 (sIL2-R) and TNFalphap75 (sTNFII-R) and usual markers of HIV infection in patients treated with protease-inhibitors (PI). Forty-six PI-naive HIV-1-infected adults were included in a 1-year prospective cohort from the initiation of a PI-containing regimen (MO). Measurements of CD4+cell count. plasma HIV-RNA, sIL2-R and sTNFII-R were performed at MO, M6. and M12. The evolution of sIL2-R from baseline to M12 was significantly different between immunological responders (IR) (CD4+count above 200/mm(3) for subject having less than 200 CD4+/mm(3) at inclusion., or increase of at least 50 CD4+/mm(3) for others) (58 UI/ml) and non-IR (+28 UI/ml) (P=0.01). The evolution of sTNFII-R between MO and M12 was significantly different between virological responders (VR) (plasma HIV-1 RNA less than 500 copies/ml at M12) (-2.5 ng/ml) and non-VR (+0.2 ng/ml) (P=0.02). Our study shows significative correlations between the evolutions of soluble interleukin-2 and TNFR-II receptors and those of CD4+T-lymphocytes or HIV-RNA responses in patients under HAART.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 24 条
[1]   Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy:: Persistent TNF activation is associated with virologic and immunologic treatment failure [J].
Aukrust, P ;
Müller, F ;
Lien, E ;
Nordoy, I ;
Liabakk, NB ;
Kvale, D ;
Espevik, T ;
Froland, SS .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :74-82
[2]   Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment [J].
Chougnet, C ;
Fowke, KR ;
Mueller, BU ;
Smith, S ;
Zuckerman, J ;
Jankelevitch, S ;
Steinberg, SM ;
Luban, N ;
Pizzo, PA ;
Shearer, GM .
AIDS, 1998, 12 (18) :2397-2406
[3]   TUMOR NECROSIS FACTOR A ACTIVATES HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 THROUGH INDUCTION OF NUCLEAR FACTOR BINDING TO THE NF-KAPPA-B SITES IN THE LONG TERMINAL REPEAT [J].
DUH, EJ ;
MAURY, WJ ;
FOLKS, TM ;
FAUCI, AS ;
RABSON, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (15) :5974-5978
[4]   Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements [J].
Fahey, JL ;
Taylor, JMG ;
Manna, B ;
Nishanian, P ;
Aziz, N ;
Giorgi, JV ;
Detels, R .
AIDS, 1998, 12 (13) :1581-1590
[5]   THE PROGNOSTIC VALUE OF CELLULAR AND SEROLOGIC MARKERS IN INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].
FAHEY, JL ;
TAYLOR, JMG ;
DETELS, R ;
HOFMANN, B ;
MELMED, R ;
NISHANIAN, P ;
GIORGI, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (03) :166-172
[6]   SOLUBLE RECEPTORS FOR TUMOR-NECROSIS-FACTOR AS PREDICTORS OF PROGRESSION TO AIDS IN ASYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
GODFRIED, MH ;
VANDERPOLL, T ;
WEVERLING, GJ ;
MULDER, JW ;
JANSEN, J ;
VANDEVENTER, SJH ;
SAUERWEIN, HP .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :739-745
[7]   Monitoring plasma HIV-1 RNA levels in addition to CD4(+) lymphocyte count improves assessment of antiretroviral therapeutic response [J].
Hughes, MD ;
Johnson, VA ;
Hirsch, MS ;
Bremer, JW ;
Elbeik, T ;
Erice, A ;
Kuritzkes, DR ;
Scott, WA ;
Spector, SA ;
Basgoz, N ;
Fischl, MA ;
DAquila, RT .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) :929-938
[8]   Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection [J].
Jacobson, JM ;
Greenspan, JS ;
Spritzler, J ;
Ketter, N ;
Fahey, JL ;
Jackson, JB ;
Fox, L ;
Chernoff, M ;
Wu, AW ;
MacPhail, LA ;
Vasquez, GJ ;
Wohl, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (21) :1487-1493
[9]   CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) [J].
Kaufmann, D ;
Pantaleo, G ;
Sudre, P ;
Telenti, A .
LANCET, 1998, 351 (9104) :723-724
[10]   The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-α) expression in acutely and chronically infected cells in vitro [J].
La Maestra, L ;
Zaninoni, A ;
Marriott, JB ;
Lazzarin, A ;
Dalgleish, AG ;
Barcellini, W .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) :123-129